Abstract:Background Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by irreversible joint destruction and disability. At present, the biggest challenge in the field of RA treatment is the emergence of multidrug resistance (MDR) in the application of disease-modifying anti-rheumatic drugs (DMARDs).The Multidrug resistance Related Protein and Multi Drug Resistance protein 1, also called P-glycoprotein can decreases the intracellular concentration of different drugs. Moreover, cytokines play an increasingly important role in the expression regulation mechanisms of P-gp, especially inflammatory cytokines IL-6. Previously, We have indicated that Interleukin-6 up-regulates P-gp in peripheral blood lymphocytes via the JAK2-STAT3 pathway in RA patients. Through more than ten-years9 clinical research, we observed that the therapeutic cycle alliance of methotrexate (MTX) and cyclophosphamide (CTX) has had better curative effect and lower rate of adverse reaction in treating RA. And we didn9t found the emergence of MDR. How can the therapeutic alliance of MTX and CTX overcome MDR in RA patients? This study will give the answer. Objectives To Clarify whether the therapeutic alliance of MTX and 4-hydroperoxycyclophosphamide (4-HC) suppress expression and mRNA of P-gp in peripheral blood lymphocytes of RA through JAK2-STAT3 pathway. Methods RA patients without any DMARDs and biologic therapy (n=15) were enrolled. P-gp expression level was detected by Flow Cytometry. P-gp mRNA of peripheral blood lymphocytes and the intracellular signaling pathway mediating the effects of MTX and 4-HC on IL-6-stimulated JAK2-STAT3 activation was assessed by RT-PCR. Results Compared with blank control group, IL-6 induced P-gp, JAK2 and STAT3 expression levels increased significantly ( P P P u003e0.05). Conclusions Our data indicated that MTX combined with CTX significantly inhibited IL-6 induced JAK2-STAT3 activation, as well as the induction of P-gp. Inhibition of IL-6-mediated multidrug resistance signaling pathways by the alliance of MTX and CTX may represents a new reversing drug-resistance therapeutic strategy for RA. References Li HX, Zhao W, Shi Y, et al. Retinoic acid amide inhibits JAK/STAT pathway in lung cancer which leads to apoptosis. Tumour Biol. 2015; 36(11): 8671–8678. Oh HM, Lee SW, Yun BR, et al. Vigna angularis inhibits IL-6-induced cellular signalling and ameliorates collagen-induced arthritis. Rheumatology (Oxford). 2014; 53(1): 56–64. Li R, Cai L, Ren DY, Xie XF, Hu CM, Li J. Therapeutic effect of 7, 39-dimethoxy hesperetin on adjuvant arthritis in rats through inhibiting JAK2-STAT3 signal pathway. Int Immunopharmacol. 2012; 14(2): 157–163. Yun M, Lee D, Park MN, et al. Cinnamaldehyde derivative (CB-PIC) sensitizes chemo-resistant cancer cells to drug-induced apoptosis via suppression of MDR1 and its upstream STAT3 and AKT signalling. Cell Physiol Biochem. 2015; 35(5): 1821–1830. Disclosure of Interest None declared

The key role of organic anion transporter 3 in the drug–drug interaction between tranilast and methotrexate

Influence of the OATP Polymorphism on the Population Pharmacokinetics of Methotrexate in Chinese Patients

Interaction Between Rhein Acyl Glucuronide and Methotrexate Based on Human Organic Anion Transporters.

Anisamide-functionalized Intelligent Polymersomes Mediate Targeted Delivery of Methotrexate into Lung Cancer Cells.

Influence of C677T Polymorphism of 5,10-Methylenetetrahydrofolate Reductase on Methotrexate Toxicity

Species difference in the inhibitory effect of nonsteroidal anti-inflammatory drugs on the uptake of methotrexate by human kidney slices

Interaction of Methotrexate with Organic-Anion Transporting Polypeptide 1A2 and Its Genetic Variants

Comprehensive Evaluation of OATP- and BCRP-Mediated Drug-Drug Interactions of Methotrexate Using Physiologically-Based Pharmacokinetic Modeling

Glycolysis aggravates methotrexate toxicity by fueling RFC1-controlled intestinal absorption in rheumatic rats

AB0100 Mtx combined with ctx inhibited il-6 induced jak2-stat3 activation and the induction of p-gp in peripheral blood lymphocytes of rheumatoid arthritis patients

The importance of inhibition of a catabolic pathway of methotrexate metabolism in its efficacy for rheumatoid arthritis

Leflunomide Increases Hepatic Exposure to Methotrexate and Its Metabolite by Differentially Regulating Multidrug Resistance–Associated Protein Mrp2/3/4 Transporters via Peroxisome Proliferator–Activated Receptor α Activation

The anthraquinone drug rhein potently interferes with organic anion transporter-mediated renal elimination

Interaction of nobiletin with methotrexate ameliorates 7-OH methotrexate-induced nephrotoxicity through endoplasmic reticulum stress-dependent PERK/CHOP signaling pathway

Investigation of the Mechanism of Therapeutic Protein-Drug Interaction Between Methotrexate and Golimumab, an Anti-TNFα Monoclonal Antibody

Non-steroidal anti-inflammatory drugs affect the methotrexate transport in IEC-6 cells.

The naturally occurring flavonoid nobiletin reverses methotrexate resistance via inhibition of P-glycoprotein synthesis

Effect of methotrexate on the urinary proteome of rats

Evaluation of transport mechanisms of methotrexate in human choriocarcinoma cell lines by LC-MS/MS

Role of NF-κB signaling pathway in methotrexate resistance of patients with rheumatoid arthritis

Site-specific contribution of proton-coupled folate transporter/haem carrier protein 1 in the intestinal absorption of methotrexate in rats